Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents.
Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents.
复制标题
DOI：
10.2337/dc09-2260
复制
发表时间：
2010-06
期刊：
影响因子：
16.2
通讯作者：
Liraglutide Effect Action in Diabetes-6 Study Group
中科院分区：
文献类型：
--
作者：
Buse JB;Sesti G;Schmidt WE;Montanya E;Chang CT;Xu Y;Blonde L;Rosenstock J;Liraglutide Effect Action in Diabetes-6 Study Group
评价从每日两次艾塞那肽转换为每日一次利拉鲁肽或连续40周利拉鲁肽治疗的疗效和安全性。在一项为期26周的随机试验（利拉鲁肽在糖尿病中的作用[LEAD]-6）中，当与口服降糖药物联合使用时，利拉鲁肽比依塞那肽更有效地改善A1 C、空腹血糖和β细胞功能稳态模型（HOMA-B），持续性恶心和低血糖较少。在LEAD-6的14周延长期中，患者从10 μg每日两次艾塞那肽转换为1.8 mg每日一次利拉鲁肽或继续利拉鲁肽治疗。从艾塞那肽转换为利拉鲁肽进一步显著降低A1 C（0.32%）、空腹血糖（0.9 mmol/l）、体重（0.9 kg）和收缩压（3.8 mmHg），伴极轻微低血糖（1.30次发作/患者-年）或恶心（3.2%）。在继续接受利拉鲁肽治疗的患者中，体重（0.4 kg）和收缩压（2.2 mmHg）进一步显著降低，轻度低血糖为0.74次/患者年，1.5%的患者发生恶心。从艾塞那肽转换为利拉鲁肽耐受性良好，并提供额外的血糖控制和心脏代谢获益。
To evaluate efficacy and safety of switching from twice-daily exenatide to once-daily liraglutide or of 40 weeks of continuous liraglutide therapy. When added to oral antidiabetes drugs in a 26-week randomized trial (Liraglutide Effect and Action in Diabetes [LEAD]-6), liraglutide more effectively improved A1C, fasting plasma glucose, and the homeostasis model of β-cell function (HOMA-B) than exenatide, with less persistent nausea and hypoglycemia. In this 14-week extension of LEAD-6, patients switched from 10 μg twice-daily exenatide to 1.8 mg once-daily liraglutide or continued liraglutide. Switching from exenatide to liraglutide further and significantly reduced A1C (0.32%), fasting plasma glucose (0.9 mmol/l), body weight (0.9 kg), and systolic blood pressure (3.8 mmHg) with minimal minor hypoglycemia (1.30 episodes/patient-year) or nausea (3.2%). Among patients continuing liraglutide, further significant decreases in body weight (0.4 kg) and systolic blood pressure (2.2 mmHg) occurred with 0.74 episodes/patient-year of minor hypoglycemia and 1.5% experiencing nausea. Conversion from exenatide to liraglutide is well tolerated and provides additional glycemic control and cardiometabolic benefits.
登录
查看更多内容
影响因子：
16.2
作者：
Kendall, DM;Riddle, MC;Baron, AD
通讯作者：
Baron, AD
影响因子：
168.9
作者：
Buse, John B.;Rosenstock, Julio;Blonde, Lawrence
通讯作者：
Blonde, Lawrence
影响因子：
16.2
作者：
DeFronzo, RA;Ratner, RE;Baron, AD
通讯作者：
Baron, AD
影响因子：
16.2
作者：
Zinman B;Gerich J;Buse JB;Lewin A;Schwartz S;Raskin P;Hale PM;Zdravkovic M;Blonde L;LEAD-4 Study Investigators
通讯作者：
LEAD-4 Study Investigators
影响因子：
16.2
作者：
Buse, JB;Henry, RR;Baron, AD
通讯作者：
Baron, AD